Royalty Pharma pays startup $525M for stake in Sanofi MS drug
Royalty Pharma Announces Dividend Increase
Royalty Pharma Highlights Accomplishments
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
PTC Announces Evrysdi Agreement with Royalty Pharma for Up To $1.5 Billion
NEW YORK, NY, October 16, 2023 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share.
NEW YORK, NY, October 11, 2023 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
NEW YORK, NY, September 21, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee.
NEW YORK, NY, September 5, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE...